| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10018686 | HBV | ENSG00000132170.24 | protein_coding | PPARG | Yes | No | 5468 | D2KUA6 E9PFX5 P37231 Q4W448 |
| TVIS10043244 | HBV | ENSG00000132170.24 | protein_coding | PPARG | Yes | No | 5468 | D2KUA6 E9PFX5 P37231 Q4W448 |
| TVIS30003460 | HIV | ENSG00000132170.24 | protein_coding | PPARG | Yes | No | 5468 | D2KUA6 E9PFX5 P37231 Q4W448 |
| TVIS30003461 | HIV | ENSG00000132170.24 | protein_coding | PPARG | Yes | No | 5468 | D2KUA6 E9PFX5 P37231 Q4W448 |
| TVIS30056264 | HIV | ENSG00000132170.24 | protein_coding | PPARG | Yes | No | 5468 | D2KUA6 E9PFX5 P37231 Q4W448 |
| TVIS30056265 | HIV | ENSG00000132170.24 | protein_coding | PPARG | Yes | No | 5468 | D2KUA6 E9PFX5 P37231 Q4W448 |
| TVIS30056266 | HIV | ENSG00000132170.24 | protein_coding | PPARG | Yes | No | 5468 | D2KUA6 E9PFX5 P37231 Q4W448 |
| TVIS20008281 | HPV | ENSG00000132170.24 | protein_coding | PPARG | Yes | No | 5468 | D2KUA6 E9PFX5 P37231 Q4W448 |
| TVIS20057660 | HPV | ENSG00000132170.24 | protein_coding | PPARG | Yes | No | 5468 | D2KUA6 E9PFX5 P37231 Q4W448 |
| TVIS20032514 | HPV | ENSG00000132170.24 | protein_coding | PPARG | Yes | No | 5468 | D2KUA6 E9PFX5 P37231 Q4W448 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | PPARG |
|---|---|
| DrugBank ID | DB00966 |
| Drug Name | Telmisartan |
| Target ID | BE0000215 |
| UniProt ID | P37231 |
| Regulation Type | partial agonist |
| PubMed IDs | 19147680; 16938288; 18580862; 15617852; 15868121; 17691961; 16154710 |
| Citations | Tagami T, Yamamoto H, Moriyama K, Sawai K, Usui T, Shimatsu A, Naruse M: A selective peroxisome proliferator-activated receptor-gamma modulator, telmisartan, binds to the receptor in a different fashion from thiazolidinediones. Endocrinology. 2009 Feb;150(2):862-70. doi: 10.1210/en.2008-0502. Epub 2009 Jan 15.@@Imayama I, Ichiki T, Inanaga K, Ohtsubo H, Fukuyama K, Ono H, Hashiguchi Y, Sunagawa K: Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gamma. Cardiovasc Res. 2006 Oct 1;72(1):184-90. Epub 2006 Jul 21.@@Kurtz TW: Beyond the classic angiotensin-receptor-blocker profile. Nat Clin Pract Cardiovasc Med. 2008 Jul;5 Suppl 1:S19-26. doi: 10.1038/ncpcardio0805.@@Yamagishi S, Takeuchi M: Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property. Med Hypotheses. 2005;64(3):476-8.@@Kurtz TW: Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-gamma activator. Acta Diabetol. 2005 Apr;42 Suppl 1:S9-16.@@Yamagishi S, Nakamura K, Matsui T: Potential utility of telmisartan, an angiotensin II type 1 receptor blocker with peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-modulating activity for the treatment of cardiometabolic disorders. Curr Mol Med. 2007 Aug;7(5):463-9.@@Yamagishi S, Takenaka K, Inoue H: Role of insulin-sensitizing property of telmisartan, a commercially available angiotensin II type 1 receptor blocker in preventing the development of atrial fibrillation. Med Hypotheses. 2006;66(1):118-20. Epub 2005 Sep 12. |
| Groups | Approved; Investigational |
| Direct Classification | Biphenyls and derivatives |
| SMILES | CCCC1=NC2=C(C=C(C=C2C)C2=NC3=CC=CC=C3N2C)N1CC1=CC=C(C=C1)C1=CC=CC=C1C(O)=O |
| Pathways | Telmisartan Action Pathway |
| PharmGKB | PA451605 |
| ChEMBL | CHEMBL1017 |
